Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Protein Subunit Vaccines × Genitourinary × Clear all
NCT02429440 2017-08-17

UroRCC

University Hospital Tuebingen

Phase 1/2 Unknown
40 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT02452307 2017-08-17

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

University Hospital Tuebingen

Phase 1/2 Unknown
36 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡